Where Does IM Cannabis Corp Stock Fall in the Drug Manufacturers - Specialty Generic Field After It Has Risen 14.29 percent This Week - InvestorsObserver
| 123330 Stock | KRW 27,150 700.00 2.51% |
About 62% of Genic's investor base is looking to short. The analysis of current outlook of investing in Genic Co suggests that many traders are alarmed regarding Genic's prospects. The current market sentiment, together with Genic's historical and current headlines, can help investors time the market. In addition, many technical investors use Genic stock news signals to limit their universe of possible portfolio assets.
Genic |
Where Does IM Cannabis Corp Stock Fall in the Drug Manufacturers - Specialty Generic Field After It Has Risen 14.29 percent This Week InvestorsObserver
Read at news.google.com
 |
Genic Fundamental Analysis
We analyze Genic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Genic is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Genic Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genic stock to make a market-neutral strategy. Peer analysis of Genic could also be used in its relative valuation, which is a method of valuing Genic by comparing valuation metrics with similar companies.
Peers
Genic Related Equities
| 139130 | Dgb Financial | 1.08 | ||||
| 086790 | Hana Financial | 0.17 | ||||
| 005940 | NH Investment | 0.07 | ||||
| 016610 | DB Financial | 0.19 | ||||
| 005945 | Nh Investment | 0.25 | ||||
| 014570 | Korean Drug | 0.61 |
Complementary Tools for Genic Stock analysis
When running Genic's price analysis, check to measure Genic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genic is operating at the current time. Most of Genic's value examination focuses on studying past and present price action to predict the probability of Genic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genic's price. Additionally, you may evaluate how the addition of Genic to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |